Posted by DP on April 14, 2002, at 23:02:06
In reply to Re: New Antidepressants in Development? » DP, posted by dennison on April 14, 2002, at 22:56:38
Why do you suppose that is? Why do we not see Selective Norepinepherine Reuptake Inhibitors or Dopamine Reuptake Inhibitors?
> Hi - Reboxetine is a biggy, the selective norepinephrine reuptake inhibitor, used in europe but currently not fda approved in usa:( bummer. There simply are no selective norepinephrine reuptake inhibitors currently avaliable in usa, reboxetine was supposedly on track for approval but as others at psychobabble have posted it was untracked from the final part 3 fda approval, yet reason seems to be a mystery..................................................................Ok other biggy is ""duloxetine"" from eli lilly the norepinephrine serotonin reuptake inhibitor, which should be avaliable in coming months . It should be quite popular because unlike effexor the norepinephrine component starts at same time as does serotonin reuptake inhibition, no need to inc. the dose to rather high level to get the norepinephrine to come into play, starts right from the initial dosage. Those are the two biggest drugs on forefront- but there's many others involving other putative mechanisms, not monoamine based, but they're a bit further off in future as far as becoming clinically avaliable!!!
poster:DP
thread:103083
URL: http://www.dr-bob.org/babble/20020408/msgs/103088.html